Advancing Drug Access through Oral Dissolvable Strip Technology Advancing Drug Access through Oral Dissolvable Strip Technology
Pharma Tech Outlook

Advancing Drug Access through Oral Dissolvable Strip Technology

Pharma Tech Outlook | Tuesday, July 07, 2026

Pharmaceutical leaders evaluating oral dissolvable strip technology face a harder question than whether the dosage form is convenient. The real issue is whether the solution can carry clinically meaningful therapies while making medication easier for patients who are poorly served by tablets, capsules and liquid formulations. Children, older adults, patients with neurological or developmental challenges and people receiving care in low-resource settings often encounter barriers that turn a prescribed therapy into an impractical routine. Water may not be available at the right time. Refrigeration may be unreliable. Liquid dosing may create measurement errors. Tablets may be difficult or impossible to swallow. For executives, these are not minor usability issues; they influence adherence, access, safety and the economic performance of a therapy across its lifecycle.

A gold-standard solution begins by treating patient acceptability as a design requirement rather than a latestage adjustment. Strips must dissolve predictably in the oral cavity, require no complex preparation and reduce the burden on caregivers. Palatability, texture, portability and ease of administration matter because a formulation that performs in the lab can still fail if patients resist using it. This is especially important in pediatric, geriatric and chronic-care environments, where treatment may continue for months and the person administering the medicine may not be a clinician. The strongest technologies make the dose feel simple without weakening the discipline behind formulation, stability and release behavior.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Load capacity is equally central. Traditional strip formats have often been limited by the amount of active ingredient they can carry, which has confined them to narrow use cases or lower-dose applications. Pharmaceutical buyers should look for technology that can accommodate a full therapeutic dose while preserving strip integrity, safety, uniformity and predictable dissolution. Without that balance, the format risks becoming a convenience feature rather than a serious delivery platform. Higher-load performance expands the addressable therapeutic range, including infectious disease, pain management and other areas where dose size has historically made strip delivery difficult.

“Oak Therapeutics’s tuberculosis work shows how the technology can match conventional pharmacokinetic expectations while improving administration for clinical and low-resource settings.”

Scalability completes the assessment. A promising formulation has limited value if it cannot move from feasibility work to clinical quantities and commercial supply. The preferred model should allow new drugs to enter a validated platform architecture, shorten development cycles and support production without excessive rework. It should also allow release timing to be tailored, since some therapies require rapid dissolution while others may benefit from slower exposure. Data-informed formulation work, controlled manufacturing and practical integration into existing care workflows all reduce the risk that an attractive technology stalls before broad use. The strongest engagements also demand regulatory awareness, early manufacturability testing and evidence that the format can fit prescribing habits, packaging requirements and distribution constraints without creating fresh friction at scale.

Oak Therapeutics stands out as a premier choice because its work aligns closely with these demands. It focuses on oral dissolvable strips that dissolve without water, support full-dose delivery and can be tuned from rapid release to dissolution over multiple hours. Its platform is built around high activeingredient loading, including more than 350 mg on a thin strip, custom dosing and scalable production methods. Its tuberculosis work shows how the technology can match conventional pharmacokinetic expectations while improving administration for clinical and low-resource settings. For pharma executives looking for a gold-standard strip platform, Oak Therapeutics merits serious consideration.

More in News

A drug discovery platform can process thousands of compounds and still leave a program with weak evidence about what will matter in patients. Throughput is useful only when the biological readout has enough disease relevance to justify the next experiment. For executives, model choice deserves close scrutiny. A system built around a narrowly defined target may move quickly yet miss compounds that improve a disease phenotype through mechanisms that are incomplete or not fully understood. Phenotypic screening can widen the search, but only if the model produces measurable effects at a pace suitable for disciplined screening. The practical comparison is between volume and interpretability. A fast assay that generates ambiguous hits can create more downstream work, while a slower but biologically coherent screen may reduce expensive follow-up. The next concern is how hits move from initial detection into a more credible development path. A useful platform should make that progression visible. Primary screening needs a clear readout, while secondary screening should test whether an observed effect holds under another biologically relevant condition. Structure-activity work then becomes more valuable because compound changes can be judged against an established phenotype rather than computational preference alone. Executives should look for a process that can reject weak candidates early and still preserve promising chemistry for further refinement. The handoff matters when a program moves from screening into preclinical work. Poorly connected stages can leave teams repeating experiments because the basis for advancing a compound was never clear enough. “Gilga-Med’s structure-activity work uses AI to predict and generate new small molecules from experimental data produced by the platform, keeping computation tied to measured biological effects.” Small-molecule discovery also raises a different tradeoff around specificity. Compounds that affect more than one pathway can create side-effect risk, yet diseases involving aging or proteotoxic stress may not reduce neatly to a single molecular target. The better question is whether the platform can distinguish useful multi-pathway activity from uncontrolled pharmacology. Evidence should show that structural features can be adjusted while the desired biological effect is retained. A discovery system that supports iterative chemistry around observed function gives development teams more room to manage that tradeoff. Artificial intelligence adds little when it is detached from proprietary experimental data. Its practical use increases when models are trained on repeated structure-activity relationships tied to measured phenotypes. That connection matters because prediction should shorten the next design cycle, not merely produce more candidate structures. Executives should examine how experimental results feed back into compound generation and whether each round creates information that sharpens the following one. The strongest platforms treat computation as part of a closed discovery loop rather than a substitute for biological testing. Long-term advantage comes from accumulating experimentally grounded relationships that make future predictions more specific to the platform’s own chemistry. Gilga-Med uses high-throughput phenotypic screening in C. elegans disease models to identify small molecules based on observed biological effects rather than a predefined target. Its discovery process starts with primary screening and uses secondary assays to test promising hits. Structure-activity refinement follows. Its structure-activity work uses AI to predict and generate new small molecules from experimental data produced by the platform, keeping computation tied to measured biological effects. The same process produced GM310, which advanced into a mouse model of hemorrhagic stroke after earlier screening work. Gilga-Med is most relevant to buyers that favor phenotype-led discovery when target biology remains uncertain. For programs built around that scientific premise, it merits serious consideration. ...Read more
Industry Overview Drug manufacturing is heading into a stretch defined by supply chain resilience, newer production technologies, tougher quality expectations and rising demand for complex medicines. Companies are putting money into biologics, advanced therapies, continuous production and digital systems, and regulators want to see mature quality management. A modern pharmaceutical facility is no longer just a production site. It’s a connected system built around quality, reliability, flexibility and traceability. Supply Resilience Becomes a Manufacturing Priority Recent disruptions exposed weak points in concentrated manufacturing networks and in reliance on a few suppliers. Drugmakers are diversifying their sourcing, building up inventory and looking harder at where critical ingredients and finished medicines are made. The World Health Organization now treats sustainable local manufacturing as a key part of resilient health systems and global health security. Its 2026 discussions have stressed stronger manufacturing ecosystems for medicines, vaccines and diagnostic products. Regulators are moving too. In 2026 the U.S. Food and Drug Administration launched its PreCheck pilot, which gets companies talking to regulators earlier while they develop new manufacturing facilities. The program aims at better regulatory predictability, along with more production capacity and stronger supply resilience. Quality Management Moves Beyond Compliance Good manufacturing practice is still the foundation of drug production, but regulators care more about whether manufacturers can hold quality steady over time. Under the FDA’s Quality Management Maturity program, manufacturers are urged to adopt practices beyond baseline current good manufacturing practice requirements. It aims at stronger quality culture, continuous improvement and less risk of supply disruption. Quality metrics are becoming practical management tools in this climate. Manufacturing teams can track measures like deviations, process performance, batch reliability and recurring quality issues to spot weaknesses before they turn into major failures. That shifts quality away from mostly inspection-driven work and toward a continuous manufacturing discipline. Advanced Manufacturing Changes Production More drug producers are adopting automation, continuous processing, advanced process controls and data-driven manufacturing systems. These tools can make processes more consistent and give manufacturers better visibility into production conditions. The FDA’s Advanced Manufacturing Technologies Designation Program exists to push wider adoption of technologies that can improve manufacturing reliability, product quality and drug supply. Digital systems support electronic batch records, laboratory integration, equipment monitoring and production analytics as well. Artificial intelligence could help with predictive maintenance, process monitoring and anomaly detection, though regulated uses need proper validation and governance. Technology pays off when it solves a specific manufacturing problem. Automation without solid process understanding can add complexity instead of improving performance. “Every technological and organizational improvement has to support the consistent manufacture of medicines that meet established standards for quality, safety and reliability.” Biologics Increase Manufacturing Complexity Drug portfolios are shifting toward products that demand far more sophisticated production capabilities. Biologics, biosimilars, cell and gene therapies and other complex products can require specialized facilities, sensitive processes and demanding analytical work. That means manufacturers need capabilities in process development, analytical testing, contamination control, coldchain management and specialized equipment. Flexibility in production is gaining value as product portfolios grow more diverse and batch sizes can swing widely. Contract development and manufacturing organizations have now become important partners for companies that want specialized capacity without building every capability in-house. Their value increasingly rests on technical depth, regulatory experience, technology transfer capability and reliable quality systems. Data Integrity Supports Manufacturing Reliability Drug production generates extensive data from manufacturing equipment, laboratory systems, environmental monitoring and quality processes. Records need to be accurate, attributable and traceable, since manufacturing decisions rest on that information. Data integrity is also closely tied to product quality. Poorly controlled electronic systems can create risks that reach beyond documentation. Batch release decisions, investigations and regulatory confidence can be affected. More manufacturers are combining production and quality data to find patterns across processes. Collecting more information isn’t the point in itself. Reliable data matters when it leads to earlier intervention and better process control. Sustainability Enters Facility Design Drug manufacturers also face mounting pressure to cut resource use and environmental impact. Facilities can consume large amounts of water, energy, solvents and specialized materials. Manufacturers are seeking gains in energy efficiency, solvent recovery, water optimization, waste reduction and more efficient production processes. Facility design is a good place to start, since environmental improvements are often easier to include during construction than after commissioning systems. Sustainability must still be weighed against validated production requirements. Changes to utilities, materials or processes can alter product quality, which calls for proper assessment and control. Regulatory Visibility Is Expanding Regulators are now looking harder at manufacturing networks, including facilities that contribute indirectly to the supply of finished medicines. In July 2026 the FDA proposed changes to clarify registration requirements for certain foreign establishments involved in drug and active pharmaceutical ingredient manufacturing, and to create a streamlined registration approach for some distributed manufacturing models. The proposal fits a wider move toward greater visibility across pharmaceutical supply chains. Manufacturers and sponsors need clearer insight into suppliers, manufacturing locations and dependencies that could affect product availability. The Outlook for Pharma Manufacturing Drug manufacturing is moving toward a model that pairs resilient supply networks, mature quality systems and advanced production technologies. The strongest manufacturers won’t necessarily be the ones with the biggest facilities. The winners will be companies that keep quality consistent while adapting production to changing product portfolios, regulatory expectations and supply conditions. Future competitiveness will depend on how well manufacturers connect science, engineering, quality and data. Drug production is getting more sophisticated, yet its core objective hasn’t changed. Every technological and organizational improvement has to support the consistent manufacture of medicines that meet established standards for quality, safety and reliability. ...Read more
In recent years, researchers combining computer science and biology have found it relatively easy to obtain funding to bring their innovations to the commercial market. The idea was simple: by leveraging large datasets, machine learning could overcome longstanding challenges in drug discovery, development, and testing. Nevertheless, many of these initial drug initiatives have encountered difficulties. It is crucial for both the field and patients to comprehend the reasons behind these setbacks and to address these developmental challenges. Patient Data is Fundamental Transferring cutting-edge knowledge from academic laboratories to address specific technical challenges using clearly defined datasets has been established as a successful strategy in technology and biotechnology. However, integrating Artificial Intelligence (AI) into medicine—frequently referred to as 'techbio'—tends to comprehensively emphasize biological aspects over technological ones. The data essential for success in this domain is typically more diverse, sourced from various locations, and, importantly, derived from actual patients within the intricate landscape of different healthcare environments. Staying Close to Academia: In the development of medicine, human intelligence must take precedence over artificial intelligence both initially and subsequently. This intelligence is predominantly found within universities and research hospitals. Therefore, a vital component in enhancing the efficacy of AI in the creation of superior medical solutions is the establishment of robust and enduring collaborations with these academic and research institutions. This process is not merely unidirectional; it constitutes a network of continuous engagement among academia, pharmaceutical companies, and biotechnology firms. Innovative collaboration methods, such as privacy-preserving federated learning, enable training machine learning models on extensive multimodal datasets without the need to transfer them. This approach can significantly advance fundamental research, diagnostics, and drug discovery, yielding numerous patient advantages while safeguarding privacy and optimizing the utilization of diverse data sources. Multi-Dimensional Problems Require Multimodal Data: At this point in the evolution of artificial intelligence within medicine, it is evident that AI provides us with a novel perspective on human biology. For instance, a single digital pathology slide encompasses a volume of data comparable to that of a feature-length film, and only through machine learning can we fully leverage this information. However, to comprehend diseases and influence their trajectories, it is crucial to acknowledge the intricate nature of biology across all levels—from molecules to cells, tissues, the disease microenvironment, and the organism in its entirety. To achieve this, advancing AI capabilities beyond unimodal tasks is imperative. We must integrate medical imaging with cutting-edge molecular profiling technologies that capture the activity and localization of biomolecules, known as spatial omics, thereby connecting the microscopic with the macroscopic. By combining AI with such comprehensive datasets, we can gain insights into diseases, from their predisposition to their progression and treatment. ...Read more
Drug discovery is a complex, multi-step process focused on identifying new therapeutic compounds and delivering them to market. Despite progress in technology and science, the path from discovery to an approved drug remains filled with challenges. These include high costs, extended timelines, and scientific uncertainties. This article examines the main hurdles in drug discovery and outlines strategies to overcome them. High Costs and Financial Risks One of the primary obstacles in drug discovery is the substantial financial burden linked to research and development (R&D). Typically, the process requires more than ten years and expenditures amounting to billions of dollars before introducing a new drug. The financial risk is substantial, as many potential drugs fail during clinical trials, leading to significant losses for pharmaceutical companies. Investment in Early-Stage Research: To mitigate financial risks, companies increasingly invest in early-stage research to identify promising compounds before committing to expensive clinical trials. Collaborations and Partnerships: Strategic partnerships with academic institutions, biotech firms, and other pharmaceutical companies can help share the financial burden and pool resources for drug development. Lengthy Timelines The drug discovery process is notoriously time-consuming. It involves multiple stages, including target identification; lead compound discovery, preclinical testing, and clinical trials. Each stage can take several years, and delays are common due to regulatory requirements and unforeseen scientific challenges. Streamlining Processes: Implementing efficient project management practices and leveraging technology can help streamline the drug discovery process. For example, using artificial intelligence (AI) and machine learning (ML) to analyze data can accelerate target identification and lead optimization. Regulatory Collaboration: Engaging with regulatory agencies early in development can help identify potential hurdles and expedite approval. Scientific Complexities Drug discovery is inherently complex due to the biological intricacies of diseases and the need for precise targeting of therapeutic compounds. Understanding disease mechanisms, identifying suitable targets, and designing effective drugs require advanced scientific knowledge and sophisticated technologies. Advanced Technologies: Cutting-edge technology such as CRISPR gene editing, high-throughput screening, and computer modeling can help us understand disease causes and improve medication design. Interdisciplinary Approaches: Combining expertise from various scientific disciplines, including biology, chemistry, and pharmacology, can result in more innovative solutions and a better understanding of complex biological systems. High Attrition Rates The attrition rate in drug discovery is notably elevated. Numerous compounds do not succeed in clinical trials owing to issues related to efficacy or safety. This high failure rate contributes to the cost and time required to develop new drugs. Predictive Models: The utilization of artificial intelligence and machine learning in the development of predictive models can facilitate the early identification of potential failures in the process, enabling researchers to concentrate their efforts on the most promising candidates. Biomarkers and Diagnostics: Incorporating biomarkers and diagnostic tools in clinical trials can improve patient selection and increase the likelihood of success by targeting specific populations more likely to respond to the treatment. ...Read more

Weekly Brief